See full Prescribing Information for complete boxed warning.
DUEXIS, a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
This product information is intended for US Health Care Professionals and Consumers only.
© 2011 Horizon Pharma. All rights reserved. 0043DUEX02
DUEXIS is a registered trademark of Horizon Pharma